To the content
4 . 2021

The cervical cancer prevention in Russia

Abstract

The rapid increase in morbidity and mortality from cervical cancer of reproductive age, the Lack of organized cervical screening are relevant at the present time in RF. The development of a system for organized screening of cervical cancer is the task of today. The aim of the article is to analyze the state and prospects of the cervical cancer screening system in Russia and world from the leading Russian professionals: cytologists, molecular biologists, oncologists, gynecologists, public health workers, etc.

Keywords:cervical cancer screening, human papillomavirus (HPV), HPV test, cytology

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Rogovskaya S.I., Shabalova I.P., Ulumbekova G.E., Korolenkova L.I., Bebneva T.N., Gushchin A.E., Kira E.F., Kondrikov N.I., Kononova I.N., Ledina A.V., Leshkina G.V., Mingaleva N.V., Mogirevskaya O.A., Podzolkova N.M., Polonskaya N.Yu., Smirnov V.V., Firichenko S.V., Shipulina O.Yu. The cervical cancer prevention in Russia. ORGZDRAV: novosti, mneniya, obuchenie. Vestnik VSHOUZ [HEALTHCARE MANAGEMENT: News, Views, Education. Bulletin of VSHOUZ]. 2021; 7 (4): 16-31. DOI: https://doi.org/10.33029/2411-8621-2021-7-4-16-31 (in Russian)

REFERENCES

1. Order No. 270 of September 12, 1997 «On measures to improve the organization of cancer care for the population of the Russian Federation». (in Russian)

2. Malignant neoplasms in Russia in 2015 (morbidity and mortality). In: A.D. Kaprin, V.V. Starinsky, G.V. Petrova (eds). Moscow: MNIOI im. P.A. Gertsena, 2017: 250 p. URL: http://www.oncology.ru/service/statistics/malignant_tu-mors/2015.pdf (in Russian)

3. Shakirov K.T., Khasanov R.Sh., Gabitova S.E., Rab-baniev I.F., Nagumanov E.V., Karpenko L.G. Organization of screening for cervical cancer in the Republic of Tatarstan. Povolzhskiy onkologicheskiy vestnik [Volga Oncological Bulletin]. 2012; (4). URL: http://oncovestnik.ru/index.php/arkhiv/item/330-organizatsiya-skrininga-raka-shejki-matki-v-respublike-tatarstan (in Russian)

4. The state of cancer care for the population of Russia. In: A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow, 2020: 239 p. (in Russian)

5. Order of the Ministry of Health of Russia No. 11-30n «On approval of the procedure for the provision of medical care in the profile of “obstetrics and gynecology”». (in Russian)

6. World Health Organization. Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem. URL: https://www.who.int/activities/a-global-strategy-for-elimination-of-cervical-cancer (date of access June 2, 2020)

7. Firichenko S.V., et al. «Pitfalls» of cervical screening. Doctor.ru. 2018; 2 (146): 26-34. (in Russian)

8. Singer A., Coppleson M., Canfell K. A real time optoelectronic device as an adjunct to the Pap smear for cervical screening: a multicentre evaluation. Int J Gynecol Cancer. 2003; 13: 804-11.

9. Ozgu E., Yildiz Y., Ozgu B.S., Oz M., Dani§man N., Gungor T. Efficacy of a real time optoelectronic device (TruScreen™) in detecting cervical intraepithelial pathologies: a prospective observational study. J Turk Ger Gynecol Assoc. 2015; 16 (1): 41-4. DOI: https://doi.org/10.5152/jtgga.2015.15199 PMID: 25788849; PMCID: PMC4358311.

10. Long S., Lei W., Feng Y., Lv D., Cai Y,. Yang P. The feasibilities of TruScreen for primary cervical cancer screening: a self-controlled study. Arch Gynecol Obstet. 2013; 288 (1): 113-8. DOI: https://doi.org/10.1007/s00404-012-2697-4 Epub 2013 Jan 8. PMID: 23296464.

11. Wei Y., et al Clinical evaluation of a real-time optoelectronic device in cervical cancer screening. Eur J Obstet Gynecol Reprod Biol. 2021; 266: 182-6. DOI: https://doi.org/10.1016/j.ejogrb.2021.09.027

12. Chen F., Zhao Yu., Li T., Chen W., Liu J., Wang J., Guo H., Zhang Y., Lang J. Clinical value of TruScreen in early diagnosis of cervical cancer and precancerous lesions: a hospital-based multicenter study. Chin J Pract Gynecol Ob-stet. 2021; 37 (3): 348-52.

13. Yang H., Zhang X., Hao Z. The diagnostic accuracy of a real-time optoelectronic device in cervical cancer screening: a PRISMA-compliant systematic review and metaanalysis. Medicine (Baltimore). 2018; 97 (29): 11439. DOI: https://doi.org/10.1097/MD.0000000000011439 PMID: 30024517; PMCID: PMC6086506.

14. Bebneva T.N., Prilepskaya V.N., Tagieva A.V. The effectiveness of the TruScreen optoelectronic technique in the diagnosis of precancerous processes of the cervix. Akusher-stvo i ginekologiya [Obstetrics and Gynecology]. 2012; (5): 58-62. (in Russian)

15. Minkina G.N., Khramova O.K., Firichenko S.V. Clinical efficacy of truscreen optoelectronic technology in the diagnosis of cervical intraepithelial neoplasia. Vestnik Rossiyskogo gosudarstvennogo meditsinskogo universiteta [Bulletin of Russian State Medical University]. 2011; (4): 37-42. (in Russian)

16. Jeronimo J., et al. Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. Published online 12.10.2016. URL: http:// www.asco.org/rs-cervical-cancer-secondary-prev-guideline

17. US Preventive Services Task Force Draft Recommendation Statement. Cervical Cancer: Screening. Rockville, MD: AHRQ, September 12, 2017. URL: http://www.uspreventiveservicestaskforce.org/Page/Document/draf-recommendation-statement/cervical-cancer-screening2

18. Comprehensive Cervical Cancer Control. A Guide to Essential Practice. 2nd ed. Geneva: World Health Organization, 2014.

19. The Bethesda System for Reporting Cervical Cytology. ASCCP, 2001, 2012, 2014.

20. Cervical intraepithelial neoplasia, erosion and ectropion of the cervix. Clinical guidelines of the Ministry of Health of the Russian Federation. Moscow, 2020: 59 p. (in Russian)

21. Arbyn M., et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann Intern Med. 2017; 166: 118-27.

22. Perkins R.B., Guido R.S., Castle P.E., et al. 2019 ASCCP Risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020; 24: 102-31.

23. Nayar R., Chhieng D.C., Crothers B., Darragh T.M., Davey D.D., Eisenhut C., et al. Moving forward-the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories. J Am Soc Cytopathol. 2020; 9 (4): 291-303.

24. Vincini G., Cabuang L. Quality assurance for HPV testing in Australia. Abstracts EUROGIN 2019. FC 01 - HPV testing and genotyping: 0360.

25. Meijer M., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women of 30 years and older. Int J Cancer. 2009; 124 (3): 516-20.

26. Fontham E.T., Wolf A.M., Church T.R., et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American cancer society. CA Cancer J Clin. 2020; 70 (5): 321-35.

27. Cheung L.C., Egemen D., Chen X., et al. ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation. J Lower Genit Tract Dis. 2020; 24 (2): 90-101.

28. Liverani C.A., Giuseppe J., Giannella L., Car-pini G.D., Ciavattini A. Cervical cancer screening guidelines in the postvaccination era: review of the literature. J Oncol. 2020; 2020: 8887672. 14 p. DOI: https://doi.org/10.1155/2020/8887672

29. Ronco G. Core elements of the new HPV-based cervical cancer screening programme in Italy. 2018. No. 69. URL: www.HPVWorld.com

30. Wright T.C., Stoler M.H, Behrens С.М., et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136 (2): 189-97.

31. Han В., Fu Y., Li X., Li L., Zhu X., Zhang C., et al. Hybrid capture HPV test with hpv16/18 genotyping provides a new way for cervical cancer screening: a 3-year follow-up trial. Abstract IPVC. 2021. P. 51.

32. Arbyn M., Latsuzbaia A. Meta-analysis of the clinical accuracy of HR HPV DNA testing on urine versus on clinician -taken cervical samples. Abstract IPVC. 2021. P. 57-58.

33. Gillis J., Donken R., Cook D., Smith L. Use of urine specimens for the detection of genital HPV infection in males and females: protocol for a systematic review and meta-analysis. Abstract IPVC. 2021. P. 143.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Guzel E. Ulumbekova
MD, MBA from Harvard University (Boston, USA), Head of the Graduate School of Healthcare Organization and Management (VSHOUZ)

Journals of «GEOTAR-Media»